Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 79,350 Shares

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 79,350 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $6,419,415.00. Following the completion of the transaction, the chief executive officer now directly owns 453,894 shares in the company, valued at $36,720,024.60. This represents a 14.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Trading Down 1.0 %

Shares of NASDAQ:INSM traded down $0.83 on Friday, reaching $79.95. 1,690,520 shares of the company traded hands, compared to its average volume of 1,955,787. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $82.04. The stock has a market capitalization of $14.30 billion, a P/E ratio of -14.41 and a beta of 1.11. The business’s 50-day simple moving average is $72.79 and its 200 day simple moving average is $73.10.

Institutional Investors Weigh In On Insmed

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in Insmed by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after purchasing an additional 172,664 shares during the period. Principal Financial Group Inc. raised its holdings in Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after purchasing an additional 214,130 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after purchasing an additional 850,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Insmed by 7.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,546,607 shares of the biopharmaceutical company’s stock valued at $106,778,000 after buying an additional 102,341 shares during the period. Finally, Wellington Management Group LLP grew its holdings in shares of Insmed by 2.6% during the 3rd quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company’s stock worth $70,260,000 after acquiring an additional 24,025 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on INSM shares. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday. Guggenheim boosted their target price on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. increased their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.